# DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours

Source: https://onco.cc/trials/nct05582850/  
OnCo record `nct05582850` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DT-9081 run by Domain Therapeutics SA, terminated.

## Summary

DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours is a phase 1 interventional study registered as NCT05582850 by Domain Therapeutics SA, with 29 participants enrolled, started 2022-11-24. Conditions recorded: Solid Tumor, Adult. Interventions recorded: DT-9081 - dose escalation and DT-9081 - expansion.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05582850
- Phase: 1
- Setting: A Phase 1, Multicentre, Open-label, Dose-escalation and Expansion Study to Determine a Recommended Phase 2 Dose (RP2D) of DT-9081 in Participants With Advanced Solid Tumours
- Sponsor: Domain Therapeutics SA
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT05582850: https://clinicaltrials.gov/study/NCT05582850

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [DT-9081](https://onco.cc/drugs/dt-9081/)
- companies: [Kainova Therapeutics](https://onco.cc/companies/domain-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05582850.json